Bioinfra Co., Ltd. (199730) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bioinfra Co., Ltd. (199730:KRX), powered by AI.

Current Price
₩3,180
P/E Ratio
-1.7
Market Cap
15.5B
Sector
Healthcare
What is the Bioinfra Co., Ltd. stock price forecast?

Bioinfra Co., Ltd. is currently trading at ₩3,180. View real-time AI analysis on Alpha Lenz.

What is Bioinfra Co., Ltd. insider trading activity?

View the latest insider trading data for Bioinfra Co., Ltd. on Alpha Lenz.

What is Bioinfra Co., Ltd.'s P/E ratio?

Bioinfra Co., Ltd.'s P/E ratio is -1.7.

Bioinfra Co., Ltd.

KRX · 199730
₩3,180+105(+3.41%)Market closedKRX regular session 09:00–15:30 KST
Ask about Bioinfra Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Bioinfra Co., Ltd. trades at a P/E of -1.7 (undervalued) with modest ROE of -41.4%.

Ask for details

Company Overview

Bioinfra Co., Ltd. is a biotechnology company specializing in the development and commercialization of innovative medical devices and diagnostic products. The primary function of the company is to enhance healthcare outcomes by providing cutting-edge solutions that improve the accuracy and efficiency of diagnostics. Bioinfra's product portfolio includes advanced testing kits and devices that cater to various medical fields, such as oncology, infectious diseases, and personalized medicine. By focusing on research and development, Bioinfra Co., Ltd. impacts the biotechnology sector significantly, contributing to advancements in early detection and treatment methodologies. The company's role in the financial market is tied to the growing demand for reliable and efficient diagnostic tools, especially as global health challenges become more complex and prevalent. With its commitment to innovation and quality, Bioinfra Co., Ltd. aligns itself with the needs of healthcare providers, laboratories, and research institutions, facilitating improvements in patient care and medical research efficiency. Its operations underscore a vital segment of the market that continues to expand as the need for advanced healthcare solutions rises globally.

CEO이상득
SectorHealthcare
IndustryBiotechnology
0

Company Statistics

FY 2025

Profile

₩15,468,687,060Market Cap
₩23,148,010,700Revenue
4.86MShares Out
0Employees

Margins

23.00%Gross
-10.91%EBITDA
-27.08%Operating
-35.10%Pre-Tax
-39.45%Net

Valuation

-1.69P/E
0.94P/B
0.67EV/Sales
-9.97EV/EBITDA
-5.11P/FCF

Growth (CAGR)

-13.23%Rev 3Yr
3.37%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-24.00%ROA
-41.45%ROE
-20.39%ROIC

Financial Health

₩2,144,235,820Cash & Cash Equivalents
₩16,325,125,810Net Debt
111.99%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Bioinfra Co., Ltd. (ticker: 199730) is a company listed on KRX in the Healthcare sector (Biotechnology). Market cap is $15.5B.

The current price is ₩3,180 with a P/E ratio of -1.69x and P/B of 0.94x.

ROE is -41.45% and operating margin is -27.08%. Annual revenue is $23.1B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Bioinfra Co., Ltd. (199730) Stock Forecast 2026 ₩3,180 — Price, Financials & Analyst Targets | Alpha Lenz